Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Biotech
Amgen reports first phase 3 win for $400M eczema drug
While the trial met its primary endpoints, Amgen still needs to make the case that there is a role for rocatinlimab in a market served by Dupixent.
Nick Paul Taylor
Sep 25, 2024 5:50am
Generate gains another $1B-plus Big Pharma partner in Novartis
Sep 24, 2024 6:00am
Amgen, Merck join academic clinical trial diversity partnership
Sep 16, 2024 3:10pm
Viridian eye disease phase 3 hits, advancing push to rival Amgen
Sep 10, 2024 8:10am
Acelyrin loses interest in izokibep, lays off 3rd of staff
Aug 13, 2024 4:00pm
UPDATE: Amgen axes an obesity asset, zooms in on MariTide
May 2, 2024 6:16pm